Haleon: 2024 results prompt profit-taking

(CercleFinance.com) - On Thursday, Haleon reported annual results for 2024 in line with expectations and an unsurprising outlook for 2025, which nevertheless caused its share price to fall on the London Stock Exchange.


The owner of Sensodyne toothpaste, Voltaren gel and Advil painkiller, said it recorded organic sales growth of 5% last year, including 6.8% in the fourth quarter.

The group, which will be spun off from British laboratory GSK in 2022, said the price effect was 3.7%, while volumes rose by 1.3%.

On a reported basis, sales for 2024 were down by 0.6%.

For 2025, Haleon forecast annual organic sales growth of between 4% and 6%, in line with its long-term forecasts and analysts' expectations.

Despite this solid publication, the share price lost almost 3% on the London Stock Exchange on Thursday, suffering one of the biggest falls on the FTSE 100 index, a victim of profit-taking after having gained more than 10% over the last three months.

Copyright (c) 2025 CercleFinance.com. All rights reserved.